文献速递间质性肺疾病

2016至2022年美国结节病治疗模式

Sarcoidosis Treatment Patterns in the United States: 2016-2022.
PubMed 文献 · Chest · 2024-11-09

该研究基于TriNetX多中心全支付方理赔数据库,回顾性分析2016至2022年13330例结节病患者确诊后1年内的治疗模式。42.5%患者接受治疗,其中60%单用激素、13%单用非甾体免疫抑制剂、27%两者联用;25%治疗患者以非甾体免疫抑制剂为首药。治疗相关因素与指南推荐一致,但非甾体免疫抑制剂的选择和顺序差异较大。

要点

  • 确诊后1年内42.5%的结节病患者启动治疗。
  • 治疗患者中60%单用激素,40%使用非甾体免疫抑制剂。
  • 非甾体免疫抑制剂的选择与顺序实践差异大。

核心结论

  • 确诊后1年内43%的结节病患者启动治疗,非甾体免疫抑制剂用于40%的治疗患者。
  • 治疗启动相关因素与指南推荐一致,但治疗模式尤其非甾体免疫抑制剂的选择和顺序存在差异。

研究设计与样本

  • 回顾性分析2016至2022年多中心全支付方理赔数据库(TriNetX)中的结节病患者。
  • 纳入13330例结节病患者,评估确诊后1年内皮质类固醇和/或非甾体免疫抑制药物的治疗情况。
  • 采用平均秩次总结用药顺序,多因素logistic回归分析治疗相关因素。

主要发现

  • 13330例患者中5671例(42.5%)在确诊后1年内接受治疗。
  • 治疗患者中60%单用激素,13%单用非甾体免疫抑制剂,27%两者联用。
  • 25%的治疗患者以非甾体免疫抑制剂作为首药;激素平均秩次最低,平均最先启动。
  • 肺或皮肤受累者平均第二种药物为羟氯喹;心脏受累者为阿达木单抗;神经受累者为吗替麦考酚酯。
  • 治疗 odds 较高的因素包括黑人种族、基线器官受累(肺、心脏、神经)及合并症(疲劳、高钙血症、间质性肺疾病)。

临床怎么用

  • 美国真实世界中结节病治疗以激素为主,非甾体免疫抑制剂使用常见但选择与顺序变异大。
  • 临床启动治疗时可参考与指南一致的器官受累及合并症因素,但非甾体免疫抑制剂方案需个体化。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited US Food and Drug Administration-approved medications and real-world data on sarcoidosis treatment in the United States. Concordance of practice patterns with guideline recommendations have not been well characterized. RESEARCH QUESTION: What are the practice patterns and factors associated with treatment for patients with sarcoidosis in the year following diagnosis? STUDY DESIGN AND METHODS: A retrospective analysis was conducted of patients with sarcoidosis from 2016 to 2022 using a multicenter, all-payer claims database (TriNetX). Treatments with corticosteroids and/or nonsteroidal immunosuppressive medications (methotrexate, mycophenolate, leflunomide, hydroxychloroquine, cyclophosphamide, infliximab, adalimumab, azathioprine, rituximab, and Janus kinase inhibitors) within 1 year of diagnosis were ascertained. We summarized treatment rates and sequence of prescribed medications by mean rank, and used multivariable logistic regression analyses to identify factors associated with treatment. RESULTS: Of 13,330 patients with sarcoidosis meeting inclusion, 5,671 (42.5%) received treatment within 1 year of diagnosis. Of those treated, 60% received steroids alone, 13% received nonsteroidal immunosuppressives alone, and 27% received both. Furthermore, 25% of treated patients received a nonsteroidal immunosuppressive as their first medication. Corticosteroids had the lowest mean rank order, indicating they were, on average, the first medication initiated. Among those with pulmonary or cutaneous involvement, the second medication initiated, on average, was hydroxychloroquine; in those with cardiac or neurologic involvement, it was adalimumab and mycophenolate, respectively. Factors associated with higher odds of treatment were Black race, organ involvement at baseline (pulmonary, cardiac, and neurologic), and comorbid diagnoses (fatigue, hypercalcemia, and interstitial lung disease). INTERPRETATION: Within the first year of diagnosis, 43% of patients with sarcoidosis were started on treatment. Nonsteroidal immunosuppressives were used in 40% of treated patients. Although factors associated with treatment initiation aligned with guideline recommendations, practice patterns of treatment were variable, particularly in choice and sequence of nonsteroidal immunosuppressive therapy, underscoring the need for future trials and comparative effectiveness studies.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Sangani R, Bosch NA, Govender P, et al. Sarcoidosis Treatment Patterns in the United States: 2016-2022. Chest. 2024. PMID: 39522595. doi:10.1016/j.chest.2024.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。